Pharvaris N.V. Ordinary Shares(PHVS)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$30.79
52-Week Range
$16.00 – $33.33
YTD
+16.27%
IV Rank (30D)
64.21
Straddle Price
$8.05
P/C Vol Ratio
10.00
Market Cap
$2.3B
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)10.03% (VRP-adj)
WACC10.01%
Volatility Risk Premium+71.2pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$29.59 (Market Anchor value)
SMA 20 / Bollinger Mid$30.29
Bollinger Width / SMA2044.1% (drives anchor stability)
Net Debt$0.0B
Peers used for multiples: ALNY, AMGN, BIIB, GILD, ILMN, REGN, RVMD, VRTX
Blended Fair Value
Current Price
$32.20
Deviation
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 23.4× · 7 peers
Peer EV/EBITDA n/a 0% median 15.1× · 7 peers
Peer P/B n/a 0% median 7.8× · 8 peers
Peer P/S n/a 0% median 5.1× · 7 peers
Market Anchor (SMA50) $29.59 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-12 · updated 2026-06-12 09:30:40.666000
Info
Exchange
XNAS
Market Cap
$2.3B

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studie…

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +1.07% 5
Feb +0.67% 6
Mar +0.79% 6
Apr +7.46% 6
May -7.23% 6
Jun +14.79% 6
Jul +0.57% 5
Aug -1.46% 5
Sep -2.30% 5
Oct -4.00% 5
Nov -11.90% 5
Dec +96.27% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $30.29
SMA 50: $29.62
SMA 200: $26.24
Current: $30.72
EMA 12: $30.92
EMA 26: $30.39
MACD: 0.5305 | Signal: 0.0958
BULLISH
ADX (14): 16.96
RANGE
+DI: 22.44
−DI: 11.79
Momentum Oscillators
RSI (14): 51.98
NEUTRAL
Stoch %K: 73.95
Stoch %D: 81.18
Williams %R: -53.21
Volume & Volatility
BB Upper: $32.31
BB Lower: $28.26
NEUTRAL
OBV: 10,387,048
Vol SMA 20: 350,891
Vol ROC: -56.46%
ATR: $1.53
True Range: $2.69
HV 20: 43.6%
HV 30: 48.8%
HV 60: 49.0%

Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:19.112000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall assessment: NEUTRAL with confidence level (6/10)

Key drivers:

  • Technical signals are mixed, with a bullish MACD and RSI in neutral territory
  • Recent news headlines have been mostly positive, but not significantly impacting the stock price
  • Risk metrics indicate moderate volatility, following market trends

Primary risks:

  • Earnings data is unavailable, making it difficult to assess earnings expectations
  • Options market sentiment is bearish, with a put/call volume ratio of 10.00

Investment thesis: PHVS has a neutral technical stance and mixed news sentiment. The lack of earnings data hinders risk assessment, but the options market suggests caution. With moderate volatility, this stock may be suitable for traders seeking to capitalize on price movements.

Recent news sentiment impact: Positive news headlines have not significantly impacted the stock price, likely due to the bullish MACD signal being somewhat muted by the neutral RSI reading.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BULLISH, Long-term (3-12 months): BEARISH

Support/Resistance Levels:

  • Lower: $28.26 (Bollinger Band Lower)
  • Middle: $30.29 (SMA 50)
  • Upper: $32.31 (Bollinger Band Upper)

Momentum Signals:

  • RSI interpretation: Neutral (51.98)
  • MACD signal: Bullish (0.53 / Signal: 0.10 / Histogram: 0.43)
  • Bollinger Bands position: Squeeze

Volume Analysis: Volume trends are mixed, with a volume rate of change indicating a decline in trading activity.

News & Sentiment Analysis

Recent Headlines Summary: PHVS has experienced mostly positive news headlines, focusing on product developments and corporate events.

Sentiment Assessment: Aggregate news sentiment is NEUTRAL (positive 2/5, neutral 3/5).

Catalyst Identification: No significant catalysts are imminent, but upcoming earnings data could impact the stock price.

Market Narrative: The mixed technical signals and lack of significant news catalysts suggest a neutral market narrative for PHVS.

Risk & Volatility Assessment

Beta Interpretation: Beta is 0.92 (vs SPY), indicating moderate risk relative to the broader market.

Volatility Regime: Current volatility levels are above average, but not extreme.

Options Market Signals: IV rank: 64.2% (Medium), put/call volume ratio: 10.00 (Bearish).

Downside Protection: Support levels are in place at $28.26 and $30.29, providing some downside protection.

Market Context & Positioning

Sector Performance: PHVS is slightly outperforming its sector peers, suggesting a relative strength position.

Institutional Activity: No significant institutional activity has been observed recently.

Correlation Analysis: The stock's correlation with the broader market (R-squared) is 0.18, indicating limited dependence on market trends.

Relative Valuation: PHVS appears to be trading within its historical range, suggesting no significant valuation discrepancies.

Key Levels & Action Items

Critical Price Levels:

  • Lower: $28.26 (Bollinger Band Lower)
  • Middle: $30.29 (SMA 50)
  • Upper: $32.31 (Bollinger Band Upper)

Breakout/Breakdown Levels: No specific levels have been identified, but the stock may be poised to break out or breakdown from its current trading range.

Time-Sensitive Catalysts: Earnings data is expected soon, which could significantly impact the stock price.

Risk Management: Consider using stop-loss levels at $28.26 and $30.29 for downside protection, with a position sizing consideration of 1-2% of the overall portfolio.

Generated 2026-06-12 23:45 UTC
News
Options Activity
IV Rank (30D)
64.21
IV Rank (7D)
100
Avg IV
115.0%
Straddle (30D)
$8.05
Straddle (7D)
$3.80
P/C Volume
10.00
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.92
Correlation (SPY)
17.8%
0.03
Ann. Volatility
63.7%
SPY Volatility
12.3%

Moderate volatility - stock generally follows market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

109 filers59,001,754 shares$1.65B value
# Filer Shares Value % of Total % of Float Period
1 GENERAL ATLANTIC, L.P. 8,031,252 $226.88M 13.72% 2026-03-31
2 FMR LLC Custodian 6,284,472 $177.54M 10.74% 2026-03-31
3 Foresite Capital Management IV, LLC 4,778,581 $134.99M 8.17% 2026-03-31
4 venBio Partners LLC 4,639,304 $131.06M 7.93% 2026-03-31
5 VIKING GLOBAL INVESTORS LP 3,653,310 $103.21M 6.24% 2026-03-31
6 EQT Fund Management S.a r.l. 3,424,609 $96.75M 5.85% 2026-03-31
7 DEERFIELD MANAGEMENT COMPANY, L.P. 3,126,042 $88.31M 5.34% 2026-03-31
8 Bain Capital Life Sciences Investors, LLC 2,675,509 $75.58M 4.57% 2026-03-31
9 WELLINGTON MANAGEMENT GROUP LLP Custodian 2,118,900 $59.86M 3.62% 2026-03-31
10 Commodore Capital LP 1,918,970 $54.21M 3.28% 2026-03-31
11 Novo Holdings A/S 1,750,000 $49.44M 2.99% 2026-03-31
12 Saturn V Capital Management LP 1,201,402 $33.94M 2.05% 2026-03-31
13 Point72 Asset Management, L.P. 1,007,016 $28.45M 1.72% 2026-03-31
14 Cormorant Asset Management, LP 1,000,000 $28.25M 1.71% 2026-03-31
15 Sofinnova Investments, Inc. 818,328 $23.12M 1.40% 2026-03-31
16 5AM Venture Management, LLC 797,600 $22.53M 1.36% 2026-03-31
17 Polar Capital Holdings Plc 781,016 $22.06M 1.33% 2026-03-31
18 BlackRock, Inc. Custodian 757,213 $21.39M 1.29% 2026-03-31
19 Soleus Capital Management, L.P. 702,052 $19.83M 1.20% 2026-03-31
20 Rock Springs Capital Management LP 645,533 $18.24M 1.10% 2026-03-31
21 Kynam Capital Management, LP 640,395 $18.09M 1.09% 2026-03-31
22 Patient Square Capital LP 493,000 $13.93M 0.84% 2026-03-31
23 Ikarian Capital, LLC 486,856 $13.75M 0.83% 2026-03-31
24 Elmind Capital, LP 475,750 $13.44M 0.81% 2026-03-31
25 BALYASNY ASSET MANAGEMENT L.P. 462,251 $13.06M 0.79% 2026-03-31
# Filer Notional Value % of Total Period
3 filers$2.75M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $1.28M 46.45% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $1.18M 42.96% 2026-03-31
3 SIMPLEX TRADING, LLC Custodian $290.98K 10.59% 2026-03-31
Insider Activity
Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-08 Anna Nijdam Principal Accounting Officer Sell (S) −2,670 $30.87 -$82.4K EDGAR
2026-05-26 David W. Nassif CFO / CLO Sell (S) −10,000 $30.31 -$303.1K EDGAR
2026-05-26 Viviane Monges Director Sell (S) −9,667 $30.29 -$292.9K EDGAR
2026-05-26 Anna Nijdam Principal Accounting Officer Mixed $25.35 -$78.5K EDGAR
2026-05-22 Elisabeth Bjork Director Mixed $18.68 -$212.7K EDGAR
2026-05-22 Berndt Modig Chief Executive Officer EDGAR
2026-05-20 Berndt Modig Chief Executive Officer Sell (S) −2,292 $29.22 -$67.0K EDGAR
2026-05-19 Wim Souverijns Chief Commercial Officer Sell (S) −10,000 $29.92 -$299.2K EDGAR
2026-05-19 Stefan Andreas Abele Chief Technical Ops Officer Sell (S) −8,748 $29.82 -$260.9K EDGAR
2026-05-19 Robert Glassman Director Mixed −4,667 $27.21 -$179.3K EDGAR
2026-05-13 Peng Lu Chief Medical Officer Tax (F) −226 $30.02 -$6.8K EDGAR
2026-05-05 Peng Lu Chief Medical Officer Mixed $16.38 -$390.7K EDGAR
2026-05-01 Johannes Gerardus Christiaan Petrus Schikan Director Sell (S) −32,900 $30.29 -$996.5K EDGAR
2026-05-01 Anne Lesage Chief Early Development Mixed −22,900 $22.04 -$1.30M EDGAR
2026-05-01 Peng Lu Chief Medical Officer Mixed $16.40 -$517.3K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
11 insiders · @ $30.72
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Berndt Modig Chief Executive Officer 1,087,500 $33.41M -$779.8K 4 2026-05-22
2 Johannes Gerardus Christiaan Petrus Schikan Director 384,237 $11.80M -$1.21M 2 2026-05-01
3 Anne Lesage Chief Early Development 213,319 $6.55M -$1.90M 2 2026-05-01
4 David W. Nassif CFO / CLO 120,300 $3.70M -$303.1K 1 2026-05-26
5 Peng Lu Chief Medical Officer 65,974 $2.03M -$1.21M 5 2026-05-13
6 Anna Nijdam Principal Accounting Officer 46,275 $1.42M -$307.5K 5 2026-06-08
7 Wim Souverijns Chief Commercial Officer 45,111 $1.39M -$299.2K 1 2026-05-19
8 Stefan Andreas Abele Chief Technical Ops Officer 35,194 $1.08M -$260.9K 1 2026-05-19
9 Elisabeth Bjork Director 15,167 $465.9K -$293.2K 1 2026-05-22
10 Robert Glassman Director 15,167 $465.9K -$298.2K 1 2026-05-19
11 Viviane Monges Director 5,500 $169.0K -$292.9K 1 2026-05-26
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.